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Background: Transcatheter aortic valve replacement (TAVR) success is hampered by
a relatively high rate of vascular complications, which correlates with mortality. A
trend from surgical access to percutaneous has led to a decrease in the reported
complication rate, but it is still considered a valid access strategy. The aim of this
study was to explore the vascular complication rates of surgical versus percutaneous
access for TAVR and of the two most frequently used closure devices.
Methods: From a cohort of 231 patients who underwent transfemoral TAVR, 38
(16.5%) had planned surgical access while 193 (83.5%) had percutaneous access
(Perclose ProGlide n¼160; ProStar n¼33). A comparison of the three groups’ baseline
characteristics, Valve Academic Research Consortium (VARC)-deﬁned vascular
complication, and mortality rates was performed.
Results: Baseline characteristics were mostly similar save for a higher incidence of
SAPIEN valve use in the surgical access group (71.3% percutaneous vs. 97.4%
surgical; p <0.001). Although the rate of major VARC vascular complication did not
differ between groups, (Figure) access site hematomas, major bleeding and need for
transfusion were more frequent in the surgical access group. Mortality rates at 30 days
and 1 year did not differ among the three groups. No differences were noted in
outcome when Perclose was compared with Prostar use.
Conclusions: Complete percutaneous vascular access and closure with either Perclose
ProGlide or ProStar is associated with lower rates of vascular complications compared
with surgical cut down and should be the preferred access technique in TAVR.TCT-724
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Background: It may be challenging to distinguish low-ﬂow low-gradient (LFLG)
severe aortic stenosis (AS) from pseudo-severe AS, underestimation normal-ﬂow
high-gradient (NFHG) AS, or inaccurate effective oriﬁce area (EOA) on transthoracic
echocardiography (TTE). We evaluated changes in classiﬁcation of AS by left/right
heart catheterization (LHC) over TTE ﬁndings alone.
Methods: We examined 144 consecutive individuals with severe AS on TTE (EOA
<1.0 cm2 or indexed EOA <0.6 cm2/m2) and LHC within 2 months referred for
possible transcatheter aortic valve implantation (TAVI), and after exclusion of patients
with >mild tricuspid regurgitation (n¼27), subaortic obstruction (n¼3) or non-diag-
nostic studies (n¼6). We evaluated the prevalence and hemodynamic ﬁndings of
NFHG (mean gradient >40 mmHg or peak velocity >4.0 m/sec) and LFLG severe AS
on TTE (mean gradient 40 mmHg and peak velocity 4.0 m/sec), and assessed the
frequency in which LHC reclassiﬁed AS type.
Results: Mean age was 78.98.8 years, and 58.3% were male. TTE observed a high
mean gradient in 36% (52/144) of patients, while a high peak velocity was noted in
44% (63/144). LHC observed a high gradient in 59% (85/144) of individuals. Overall,
TTE identiﬁed NFHG and potential LFLG severe AS in 46% (66/144) and 54% (78/
144) of patients, respectively. In the 78 patients with potential LFLG severe AS by
TTE, LHC reported a mean gradient >40 mmHg in 41% (32/78), consistent with TTEJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrunderestimation of gradients; in an additional 10% (8/78), LHC reported an EOA
1.0 cm2, suggesting overestimation of AS severity on TTE. In comparison to TTE
alone, the addition of LHC ﬁndings reduced the proportion of patients with potential
LFLG severe AS from 54% (78/144) to 26% (38/144)(p<0.001), while LHC
conﬁrmed the presence of severe AS in 94% (136/144) of patients.
Conclusions: TTE reporting of LFLG severe AS is common in patients referred for
TAVI. The addition of LHC hemodynamics reclassiﬁed about half of LFLG cases by
TTE as having NFHG severe AS, although LHC agreed with the overall diagnosis of
severe AS in 94% of cases. In patients with LFLG severe AS by TTE, LHC may be
useful to conﬁrm this diagnosis.
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Background: TAVI represents an emerging technology that is nowadays widely used
for the treatment of aortic-valve disease in high-risk patients. However, paravalvular
leakage (PVL) still represents a major problem and was recently shown to be associated
with increased mortality and morbidity. This study evaluates the impact of CT based
aortic-valve calciﬁcation and its distribution on the post-procedural occurrence of PVL.
Methods: From May 2008 to December 2012 a total of 369 patients were scheduled
for the treatment of aortic stenosis with a TAVI procedure either using a CoreValve-
Medtronic (n¼198), Edwards-SAPIEN (n¼164), Symetis-Acurate (n¼2) and
Medtronic-Engager prosthesis (n¼5). Of these, 260 patients with a mean logistic
EuroSCORE I of 19.312% had a preoperative CT-Scan and were included in this
study. AVCS was measured in mg and mm3 using a method analogous to the
Agatston calcium scoring of coronary arteries. The image data were analyzed sepa-
rately to determine the degree of calciﬁcation for each cusp and commissure. The
occurrence of intra- or post-procedural PVL was assessed by echocardiography and
correlated to the calcium degree and distribution.
Results: TAVI was successfully performed in 254 Patients (97.7%). A new Pacemaker
Implantation was observed in 22.4% (n¼57) of patients and MACE (Myocardial
Infarction, Stroke, major vascular complication, Death) occurred in 11.4% (n¼29) of all
cases. The mean hospital length of stay was 11.3  8.3 days. There was a statistically
relevant difference inAVCSbetweenGroupswhen correlating to the occurrence of post-
interventional PVLGrade*0-1 (550.4 377.2 mg, n¼164) and Grade 2 (755.6 470.6
mg, n¼78, p<0.001) or Grade 3 (825  460.8 mg, n¼12, p<0.05). There was no
correlation between a new pacemaker implantation and AVCS.
Conclusions: This study highlights the signiﬁcant correlation between the degree of
calciﬁcation and the occurrence of post-interventional paravalvular leakage after
TAVI procedure. Thus, preoperative AVCS calculation may represents an important
predictor for PVL and may be added to the routine list of parameters for CT planning
before TAVI. *PVL Grade 0 - none; 1 - minimal; 2 - mild; 3 – moderate
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Background: Dual anti-platelet therapy is an essential component of post- percuta-
neous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR)
management. While several trials have studied the impact of hypo-responsiveness to
clopidogrel [Platelet Reactivity Units (PRU) > 230] in PCI patients, data on the
clopidgorel hypo-responsiveness post TAVR is lacking. The objectives of the study
were to characterize predictors and outcomes of clopidogrel responders and hypo-
responders patients using Accumetrics VerifyNow (San Diego, CA) P2Y12 testing
post TAVR.
Methods: Twenty two consecutive patients underwent TAVR and platelet function
testing after initial background aspirin and 600 mg of clopidogrel. Post procedure
a daily maintenance dose of 75 mg clopidogrel was administrated. Patients' charac-
teristics, presentation [heart failure, syncope, angina] and major adverse cardiac events
(MACE) (death, acute myocardial infarction, major bleeding and re-admission) were
compared between responders and hypo-responders.
Results: Of the 22 patients 15 (68%) were hypo-responders. Comparison between the
two groups is presented in table 1. MACE rate at 30 days was similar between
responders and hypo-responders [2/7 (29%) vs. 3/15 (20%), respectively, p¼0.9)].acts/POSTER/Aortic Valve Disease and Treatment B221
